Gilead says its drug gives hepatitis C patients more cost-effective cure - (MarketWatch via NewsPoints Desk)

  • A Gilead Sciences executive indicated that the hepatitis C therapy Sovaldi is providing cost-effective treatment to patients, MarketWatch reported Wednesday.
  • Gregg Alton, executive vice president for Gilead's corporate and medical affairs, said that Sovaldi, which costs $84 000 for a 12-week course of treatment, is a cheaper option than older therapies, which cost as much as $200 000.
  • Alton acknowledged that some insurers, such as Express Scripts, have expressed concerns about the therapy's price, while UnitedHealth Group noted that the drug reduced its first-quarter profits.

To read more NewsPoints articles, click here.